Director Chernett Jorey Adds 15,000 Shares to ONCOLOGY INSTITUTE Amid Rising Investor Buzz and Bullish Market Moves

Insider Buying Continues at ONCOLOGY INSTITUTE – What It Means for Investors On July 10, 2026, director Chernett Jorey added 15,000 shares of ONCOLOGY INSTITUTE INC/THE at an average price of $5.85—just shy of the current market level of $6.05. The purchase came amid a week of heightened social‑media buzz (125 % intensity) and a modest positive sentiment score (+56), suggesting that the market is paying close attention to the company’s insider activity. Jorey’s latest buy, coupled with two earlier purchases in June, indicates a steady, incremental accumulation that investors often interpret as a sign of confidence in the firm’s long‑term prospects.

Implications for Investors and the Company’s Future The timing of Jorey’s acquisition is notable. The stock has recently climbed 9.74 % for the week and 16.37 % for the month, with a dramatic 101 % year‑to‑date gain, yet the price‑earnings ratio remains negative at –15.71. This suggests that while the market is bullish, the company’s earnings model is still under pressure. Insider buying in such an environment can act as a “green flag,” signalling that those who are closest to the company’s strategy believe the stock is undervalued relative to its growth trajectory. For investors, it provides a data point that may justify a longer‑term hold, especially if the oncology sector’s value‑based care model continues to attract payer and reimbursement incentives.

Profile of Chernett Jorey – A Pattern of Gradual Accumulation Jorey’s historic transactions—12,000 shares at $4.75 in early June and 18,000 shares at $5.02 later that month—show a pattern of incremental buying as the share price ascended. The current July purchase aligns with this trend, reinforcing the view that Jorey is building a position rather than making a speculative bet. His transactions are all for common stock, with no shares sold in the same reporting period, underscoring a long‑term investment perspective. In the context of ONCOLOGY INSTITUTE’s strategic emphasis on value‑based oncology services, Jorey’s steady accumulation could reflect confidence in the company’s ability to capitalize on emerging reimbursement models and expand its clinical trial footprint.

Broader Insider Activity – A Mixed Bag While Jorey’s purchases are the most substantial, other directors have also been active. Kimberly Tzoumakas and Mark Stolper each added shares in early July, and the Chief Medical Officer sold 23,451 shares in June. These movements illustrate a dynamic insider landscape: directors are both buying and selling, possibly balancing personal liquidity needs against strategic commitments. For investors, the net effect—more buying than selling—reinforces the narrative that insiders see value in holding long term.

Bottom Line for Analysts and Retail Investors ONCOLOGY INSTITUTE’s recent insider buying, particularly by a director who has consistently added shares as the price has risen, is a strong positive signal. It suggests that the company’s leadership believes the current valuation underestimates future earnings potential driven by its value‑based care model. Coupled with robust market performance and heightened investor buzz, the insider activity offers a compelling case for maintaining or increasing a position in ONCOLOGY INSTITUTE, provided the investor’s risk tolerance aligns with a company still operating in a high‑growth, high‑margin healthcare niche.